{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T09:31:31Z","timestamp":1776850291210,"version":"3.51.2"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dev Pharmacol Ther"],"abstract":"<jats:p>The effects of 3 days of maternal ethanol administration on the placenta and on basic somatomedin (B-SM) were investigated in the mouse. Following administration of aqueous ethanol by gavage on days 13, 14 and 15 of gestation, there was no treatment-related difference in embyonic growth or placental weight as seen on day 15. There was a significant reduction in the specific binding of [125I]B-SM by day 15 placental membranes, but no difference in serum B-SM concentrations or in the frequency or severity of degenerative changes in the placenta. We have shown that changing levels of serum B-SM over the normal course of pregnancy correspond closely to patterns of cellular proliferation and aging in the placenta. It is possible that impairment in the binding activity of B-SM receptors contributes to the premature aging observed in term placentas exposed to alcohol during pregnancy in the rodent.<\/jats:p>","DOI":"10.1159\/000457085","type":"journal-article","created":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T17:07:26Z","timestamp":1502471246000},"page":"132-144","source":"Crossref","is-referenced-by-count":5,"title":["Reduced Binding of Basic Somatomedin by Mouse Placental Membranes following Maternal Alcohol Administration"],"prefix":"10.1159","author":[{"given":"L.A.","family":"Kennedy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.S.","family":"Sheppard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Bhaumick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.H.","family":"Laverty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2017,8,11]]},"container-title":["Developmental Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000457085","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T08:31:42Z","timestamp":1776846702000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000457085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,11]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000457085","archive":["Portico"],"relation":{},"ISSN":["0379-8305","2504-2505"],"issn-type":[{"value":"0379-8305","type":"print"},{"value":"2504-2505","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,11]]}}}